N/A
Completed N=63
Chronic Neuropathy Following Chemotherapy
Peripheral Nervous System Diseases · Postoperative Pain
Source: ClinicalTrials.gov NCT02654691 ↗
Enrolled (actual)
63
Serious AEs
0.0%
Results posted
Feb 2021
Primary outcomePrimary: Chemotherapy-induced Peripheral Neuropathy — 21 participants
Summary
This is a clinical study which is a follow-up of a previous prospective questionnaire study. All patients who previously participated in the study will receive a new questionnaire and will be invited for a clinical examination.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Chemotherapy-induced Peripheral Neuropathy |
21 | — |
| PRIMARY Chemotherapy-induced Neuropathic Pain |
19 | — |
| SECONDARY Sensory Abnormalities After Chemotherapy Assessed With Quantitative Sensory Testing (QST). |
11; 18; 11; 16; 8 | — |
| SECONDARY Neuronal Excitability Changes After Chemotherapy Assessed With Threshold Tracking: Sensory |
11.0; 17.4; 10.9 | — |
| SECONDARY Anxiety and Depression Using the Patient Reported Outcomes Measurement Information System (PROMIS). |
12; 12; 16 | — |
| SECONDARY Anxiety and Depression Using the Hospital Anxiety and Depression Scale (HADS). |
4.38; 2.40 | — |
| SECONDARY Fatigue Using the Patient Reported Outcomes Measurement Information System (PROMIS). |
25 | — |
| SECONDARY Quality of Life Using EuroQol (EQ-5D). |
78.4 | — |
| SECONDARY Personality Using the 10-item Personality Inventory (TIPI). |
4.5; 4.9; 5.2; 5.2; 5.3 | — |
| SECONDARY Personality Using the International Personality Item Pool (IPIP). |
34.3 | — |
| SECONDARY Pain Catastrophizing Using the Pain Catastrophizing Scale(PCS). |
7.6 | — |
| SECONDARY Morphology of Small Fibers in Cornea After Chemotherapy by Corneal Confocal Microscopy (CCM). |
30.5; 22.8 | — |
| SECONDARY Blood Samples DNA |
58 | — |
| SECONDARY Pain Interference by Patient Reported Outcomes Measurement Information System (PROMIS). |
17 | — |
| SECONDARY Pain Descriptors by Douleur Neuropathique 4 (DN4). |
13 | — |
| SECONDARY Pain Descriptors by Neuropathic Pain Symptom Inventory (NPSI). |
23.3 | — |
| SECONDARY Neuropathy Using the Toronto Clinical Scoring System (TCSS). |
4.8 | — |
| SECONDARY Neuropathy Using the Total Neuropathy Score. |
3.9 | — |
| SECONDARY Neuropathy Using the Michigan Neuropathy Screening Instrument (MNSI). |
21 | — |
| SECONDARY Neuronal Excitability Changes After Chemotherapy Assessed With Threshold Tracking: Motor |
18.8; 21.8; 16.2 | — |
Eligibility Criteria
Inclusion Criteria
- all patients who have participated in a prospective questionnaire study
Exclusion Criteria
- Not able to visit in person.
Data sourced from ClinicalTrials.gov (NCT02654691). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.